Bluebird Bio, Inc.

60 Binney St
Cambridge, MA, 02142-1512  United States
(339) 499-9300
Company Type: Corporation Parent

bluebird bio is ready to fly in the faces of rare genetic diseases. The company is using gene therapy to develop orphan drugs for two rare diseases. Its lead drug candidate, Lenti-D, is being developed to treat childhood cerebral adrenoleukodystrophy (CCALD), a rare neurological disorder that affects boys. Its second drug candidate, LentiGlobin, is being developed to treat the blood disorders beta-thalassemia major and sickle cell disease. Both drugs will begin studies by 2014. In addition, bluebird bio partnered with Celgene to develop gene therapies for cancer. Founded in 1992 as Genetix Pharmaceuticals, the company changed its name to bluebird bio in 2010 and filed an IPO in 2013.

Try D&B Hoovers Free

Financial Statements

Financial data as of (12 month period) in USD

Annual Revenue 2019
$44.67 millionUSD

Dun & Bradstreet collects private company financials for more than 23 million companies in over 200 countries. Find out more.

Company Snapshot

Essential information for a successful call

  •  EMPLOYEES (This Site) 96
  •  EMPLOYEES (All Sites) 1090
  • ASSETS (MIL USD) 1727.424
  •  SALES (MIL USD) 44.674
  • TICKER SYMBOL BLUE
  • Incorporated 1992
  • FISCAL YEAR END DEC

Get in Touch with 23 Contacts

A D&B Hoovers Subscription is your foot in the door to Bluebird Bio, Inc. contact information.
  • Nick Leschly
    President
  • DANIEL S LYNCH
    Chairman of the Board
  • SUSANNA HIGH
    Chief Operating Officer
  • JEFFREY T WALSH
    Chief Financial Officer and Officer
See full contact details
Start Your Free Trial

Get full access to D&B Hoovers

With a Hoovers subscription you can get a comprehensive view of Bluebird Bio, Inc.

Bluebird Bio, Inc.

23
Contacts
Reach the right people with access to detailed contact information.
4
Corporate Relations
Get the big picture on a company's affiliates and who they do business with.
9
Close Industry Peers
See similar companies for insight and prospecting.